Marc Casper, Thermo Fisher CEO (Suzanne Kreiter/The Boston Globe via Getty Images)

Ther­mo Fish­er wa­gers on ear­ly can­cer di­ag­nos­tics in $2.6B cash deal for mul­ti­ple myelo­ma test mak­er

Al­ways on the look­out for the next thing to buy, Ther­mo Fish­er Sci­en­tif­ic has set­tled on an on­col­o­gy di­ag­nos­tic play­er for its lat­est ac­qui­si­tion.

The life sci­ences con­glom­er­ate is shelling out $2.6 bil­lion (£2.25 bil­lion) to ac­quire The Bind­ing Site Group from a group of pri­vate eq­ui­ty in­vestors, in­te­grat­ing a suite of di­ag­nos­tic as­says and in­stru­ments for blood can­cers and im­mune sys­tem dis­or­ders in­to its spe­cial­ty di­ag­nos­tics busi­ness.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA